ஜெர்மன் இதயம் மையம் பெர்லின் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜெர்மன் இதயம் மையம் பெர்லின். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜெர்மன் இதயம் மையம் பெர்லின் Today - Breaking & Trending Today

AI-based system for real-time prediction of complications in intensive care units

AI-based system for real-time prediction of complications in intensive care units
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.

Rhode Island , United States , Volkmar Falk , Kay Brosien , Carsten Eickhoff , Christopher Baum , Emily Henderson , Alexander Meyer , Brown University In Providence , Digital Health Accelerator , Goethe University In Frankfurt Am Main , Berlin Institute Of Health , Validation Fund , Harvard University , Data Science Group , Clinician Scientist Program , Ai Lab At Brown Center , Translational Research , German Heart Center Berlin , Berlin Institute , Professor Alexander Meyer , Fhealth Accelerator , Professor Christopher Baum , Chief Translational Research Officer , Scientific Advisory Board , Vascular Surgery ,

Marizyme Announces the Use of DuraGraft® as the Standar

11 gennaio 2021 | 11.34
LETTURA: 5 minuti
DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure
JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced as of August 2020 the Vienna Heart Center North Floridsdorf of Vienna, Austria was the first clinic worldwide to use the company s flagship product, DuraGraft® as the standard-of-care for flushing and storage of the saphenous vein grafts from harvesting through grafting in Coronary Artery Bypass Grafting (CABG) patients. ....

Ingrid Mezo , Maximilian Emmert , Martin Grabwenw , Miriam Miller , Neilj Campbell , Exchange Commission , Contacts Tiberend Strategic Advisors Inc Investorsmaureen Mcenroe , Vascular Center , Vienna Heart Center North Floridsdorf , German Heart Center Berlin , Marizyme Inc , Coronary Artery Bypass Grafting , Heart Center North Floridsdorf , Assess Outcomes , Vascular Conduits , Cardiac Surgery Center , Associate Professor , Bernhard Winkler , Vienna Heart Center North , Cardiac Surgery , Chief Executive Officer , Duragraft When , Myocardial Infarction , Repeat Revascularization , Looking Statements This , Tiberend Strategic Advisors ,

Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in [...]

11 gennaio 2021 11:38
Fonte: Adnkronos
#salute-e-benessere
DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure
JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced as of August 2020 the Vienna Heart Center North Floridsdorf of Vienna, Austria was the first clinic worldwide to use the company s flagship product, DuraGraft® as the standard-of-care for flushing and storage of the saphenous vein grafts from harvesting through grafting in Coronary Artery Bypass Grafting (CABG) patients. ....

Ingrid Mezo , Maximilian Emmert , Martin Grabwenw , Miriam Miller , Neilj Campbell , Exchange Commission , Contacts Tiberend Strategic Advisors Inc Investorsmaureen Mcenroe , Vascular Center , Vienna Heart Center North Floridsdorf , German Heart Center Berlin , Marizyme Inc , Coronary Artery Bypass Grafting , Heart Center North Floridsdorf , Assess Outcomes , Vascular Conduits , Cardiac Surgery Center , Associate Professor , Bernhard Winkler , Vienna Heart Center North , Cardiac Surgery , Chief Executive Officer , Duragraft When , Myocardial Infarction , Repeat Revascularization , Looking Statements This , Tiberend Strategic Advisors ,

Digipredict digital twin will predict the evolution of Covid-19

Under a cross-disciplinary program spearheaded by EPFL, scientists will develop an AI-based system that can predict whether Covid-19 patients will develop severe cardiovascular complications and, in the longer term, detect the likely onset of inflammatory disease.
Covid-19 comes with a range of symptoms – from a sore throat and the loss of taste to more serious ones like lung failure. But how can doctors predict how serious the disease will be when it first manifests? “The interaction between the viral infection, the host’s response, and the development of cardiovascular inflammation and injury is still poorly understood. It’s hard to know whether a patient’s symptoms will remain mild or rapidly deteriorate and trigger multiple organ failure,” says Adrian Ionescu, a professor at EPFL’s Nanoelectronic Devices Laboratory, within the School of Engineering. If doctors could use a scientific method to better understand and predict the likelihood of a patient’s condi ....

Adrian Ionescu , Wolf Hautz , Alexander Meyer , Stichting Imec , Kamiar Aminian , Jan Kerschgens , David Atienza , Martin Jaggi , University Of Twente , Optimization Laboratory , Nanoelectronic Devices Laboratory , School Of Engineering , University Of Bern , Laboratory Of Movement Analysis , Systems Laboratory , German Heart Center Berlin , Intelligent Systems , Devices Laboratory , Embedded Systems Laboratory , Movement Analysis , Machine Learning , Alexander Meyer Chief Medical Information Officer , Data Science , Executive Director , அலெக்சாண்டர் மேயர் , டேவிட் ஆதிேன்ச ,

Digipredict digital twin will predict evolution of Covid-19

© 2020 EPFL
Under a cross-disciplinary program spearheaded by EPFL, scientists will develop an AI-based system that can predict whether Covid-19 patients will develop severe cardiovascular complications and, in the longer term, detect the likely onset of inflammatory disease.
Covid-19 comes with a range of symptoms – from a sore throat and the loss of taste to more serious ones like lung failure. But how can doctors predict how serious the disease will be when it first manifests? “The interaction between the viral infection, the host’s response, and the development of cardiovascular inflammation and injury is still poorly understood. It’s hard to know whether a patient’s symptoms will remain mild or rapidly deteriorate and trigger multiple organ failure,” says Adrian Ionescu, a professor at EPFL’s Nanoelectronic Devices Laboratory, within the School of Engineering. If doctors could use a scientific method to better understand and predict the likelihood of a ....

Adrian Ionescu , Wolf Hautz , Alexander Meyer , Stichting Imec , Kamiar Aminian , Jan Kerschgens , David Atienza , Martin Jaggi , University Of Twente , Optimization Laboratory , Nanoelectronic Devices Laboratory , School Of Engineering , University Of Bern , Laboratory Of Movement Analysis , Systems Laboratory , German Heart Center Berlin , Intelligent Systems , Devices Laboratory , Embedded Systems Laboratory , Movement Analysis , Machine Learning , Alexander Meyer Chief Medical Information Officer , Data Science , Executive Director , அலெக்சாண்டர் மேயர் , டேவிட் ஆதிேன்ச ,